baber/WOPTO huggingface dataset:
Patent JP-H10501071-A (JP)
Title: 毛管内容物のラマン散乱を使用する自動化される光学アラインメント装置及び方法
IPC: G01B11/27
Filed: 1996-03-22
Abstract: (57)【要約】
毛管の内容物のラマン散乱信号を利用することによってけい光検出適用のために毛管と励起レーザビームとを光学的に整合する装置と方法が開示される。たとえば、電気泳動分離マトリックスによるラマン散乱信号が毛管の電気泳動システムにおいてアラインメントのために使用されうる。けい光物質が存在することができ、このけい光物質もまたアラインメントの目的のために使用できるが、必要なものではない。本発明は、複数の穴を有する放物面の反射装置を採用する。前記穴を通して毛管とレーザビームとが、これらが反射装置の焦点において好ましくは直角で交差するように導かれる。毛管内の物質のラマン散乱信号は一連のフィルタを経て集められる。この情報は、必要な場合、励起ビームを反射装置に導く焦点合せレンズと毛管とを変位するのに使用され、その結果ラマン散乱信号が最大にされる。最大のラマン散乱信号は、毛管と励起ビームとの適当なアラインメントを指示する。試料からのけい光のような別の信号は、それから集められる。焦点合せレンズの調整は、毛管とビームとのアラインメントが毛管内容物の分析の間ずっと維持されるように自動化される。複数の毛管のアレイの励起ビームとの連続したアラインメントもまた開示されている。
Patent JP-2001509331-A (JP)
Title: Ｄｐｓｋ復調器
IPC: H04L1/06
Filed: 1997-12-18
Abstract: (57)【要約】
遠隔インテリジェント通信システム中の呼び掛け器に用いられる、差分位相シフトキー復調器（５２）。復調器は、直交信号のうち一方を遅延し、その後、ＦＩＲ整合フィルタ（６６）とともに遅延信号と未遅延信号を結合する直交コンバイナ（６４）を含む。ＦＩＲ整合フィルタ（６６）はコンバイナ出力をフィルタリングすることにより、副搬送波上の差分位相シフトキーデータは、フィルタリングされた出力に応答して単純な遅延および積算スキーム（６８、７０）を用いて復調され得る。
Patent JP-2000507883-A (JP)
IPC: F16B5/04
Filed: 1997-12-22
Abstract: An ultrasonic fastening system wherein an ultrasonic transducer is used to insert a plurality of fasteners supported by a compressible member into two components to be joined or a single composite part to be reinforced.
Patent JP-H10500619-A (JP)
IPC: B65G47/82
Filed: 1995-05-23
Abstract: An apparatus for transporting and sorting substantially planar individual items (30) along an item travel path comprising several conveyors (60,62) following said travel path. Said conveyors co-operating in urging the items along the travel path. The apparatus further comprising a plunger/pusher means (34) for ejecting items out of the path and into specific bins corresponding to codes (33) printed on the items.
Patent JP-H11504101-A (JP)
Title: 相互の自動連結装置を備えたブレーキピストン及びパッド
IPC: F16D65/095
Filed: 1996-03-12
Abstract: (57)【要約】
本発明は、このブレーキのピストン（１）にディスクブレーキパッド（２）を付けるための装置に関するもので、このピストンは、面取部（１０１）によって境が形成されかつ内部周辺拡径部（１０２）を表わしている開放内部容積（１００）を有している。この装置は、一方では、バッキングに締結されかつギャップ（５１）を離すためバッキングから分離されたエッジ（５０）を表わしている受動的締結構成要素（５）を包含し、他方では、自動的にギャップ内に挿入される第１クリップ（６１）の手段によってパッドに締結されるピストン（１）内をスライド可能に設置され、かつ自動的にピストンの周辺拡径部（１０２）に挿入される第２クリップ（６２）の手段によってピストンに締結される能動的締結構成要素（６）を包含する。
Patent JP-2001509678-A (JP)
Title: 抗原性の組換えハイブリッド・グルタミン酸デカルボキシラーゼの酵母における発現
IPC: A61P3/10
Filed: 1998-01-21
Abstract: (57)【要約】
GAD65アイソフォーム由来の中央及びカルボキシ−末端成分に直接又は間接的に連結された、GAD67アイソフォーム由来のアミノ−末端成分を含む、抗原性ハイブリッド・グルタミン酸デカルボキシラーゼ(GAD)、及び真核宿主細胞、特に酵母内での発現による組換えタンパク質としてのその製造。
Patent JP-2000507563-A (JP)
Title: 置換アリールイミダゾール類の使用
IPC: A61K31/00
Filed: 1997-03-20
Abstract: (57)【要約】
本発明は、寄生性原虫類を防除するための、式（I）
 ［式中、Ａｒは、場合によっては置換されたアリールであり、Ｗはハロゲンアルキルであり、Ａは水素又はＣＨ 2 Ｒであり、Ｒは場合によっては置換されたアリール、又は基−ＯＲ 1 、−ＳＲ 1 もしくは−Ｎ（Ｒ 2 ）ＣＯＲ 3 の中の１つであり、並びにＹは、ハロゲン、トリフルオロメチル、ニトロ、−Ｓ（Ｏ） n Ｒ 6 、ＣＮもしくは−ＣＯＮＲ 4 Ｒ 5 、又は場合によっては置換されたアリールである。（ここで、Ｒ 1 は水素、場合によっては置換されたアルキル、シクロアルキル、アルケニル、アルキニル、アリール又はアラルキルであり、Ｒ 2 は、水素、アルキル、ハロゲンアルキル、シクロアルキル又は場合によっては置換されたアリールであり、Ｒ 3 は（Ｘ） m Ｒ 7 であり、ＸはＯ、Ｓ、−Ｎ（Ｒ 8 ） 2 −であり、ｍは０又は１であり、Ｒ 4 、Ｒ 5 、Ｒ 8 は、相互に独立して、水素、アルキル又は場合によっては置換されたアリールであり、Ｒ 6 はアルキル、ハロゲンアルキル又は場合によっては置換されたアリールであり、及びＲ 7 はアルキル、ハロゲンアルキル又は場合によっては置換されたアリール、アラルキル又はヘタリールであり、並びにｎは０、１又は２である。）］のアリール−イミダゾール類の使用に関する。
Patent JP-H11505367-A (JP)
Title: エレクトロルミネセンス形層システム
IPC: H05B33/28
Filed: 1996-02-24
Abstract: (57)【要約】
本発明は、直流電圧源に接続可能な２つの電極の間に配設される発光性有機材料を備え、第１の電極は正孔注入電極（アノード）で第２の電極は電子注入電極（カソード）である、エレクトロルミネセンス形層システムに関する。本発明は、正孔注入電極（１６）及び/又は電子注入電極（１４）が少なくとも領域毎にナノ材料から形成されることを特徴としている。
Patent JP-2001511700-A (JP)
Title: 溶液から塩素酸イオンを除去するための方法
IPC: B01J23/40
Filed: 1998-01-10
Abstract: (57)【要約】
本発明は、水素の存在下に接触処理によって溶液から塩素酸イオンを除去する方法に関する。本発明によれば、ロジウム触媒および／または白金触媒が使用される。触媒担体材料の選択は、溶液中に含有される共吸着剤の量に左右される。さらに、酸化物または非酸化物であってよい担体材料は、良好に湿潤性であるべきである。
Patent JP-2000508604-A (JP)
Title: 円盤状物体の固定器具
IPC: G11B23/03
Filed: 1997-04-15
Abstract: (57)【要約】
本発明は、コンパクトディスクやレコードのような円盤状物体の固定器具に関する。均質な厚紙または貼り合わせ板紙（ペーストボード）のようなファイバーボードでつくられたものであり、２枚のエンドプレート（５，６）、これらと結合した側部（７，８）、及び該側部内に形成された平行な溝（１０）であって一方の側から発して当該平行な溝を連結する半円状の溝（１１）に終わる溝を含み、これらの溝（１０，１１)は、物体を挿入し保管するためものであり、挿入された物体（２）と連続的に広がった前記底部エンドプレート（６）との間に、前記物体（２）の最外周部を除いて間隙が形成されるように、前記溝（１０，１１）が底部エンドプレート（６）の上方に距離を隔てて配置されていることを特徴とする。
Patent JP-2000510115-A (JP)
Title: オキシインドール誘導体
IPC: C07D403/04
Filed: 1997-05-02
Abstract: (57)【要約】
本発明は、式Ｉ：
 ［式中：Ｒ 2 はヒドロキシ、ハロゲノ、Ｃ 1 〜Ｃ 3 アルキル、Ｃ 1 〜Ｃ 3 アルコキシ、Ｃ 1 〜Ｃ 3 アルカノイルオキシ、トリフルオロメチル、シアノ、アミノ、ニトロ、Ｃ 2 〜Ｃ 4 アルカノイル、Ｃ 1 〜Ｃ 4 アルカノイルアミノ、Ｃ 1 〜Ｃ 4 アルコキシカルボニル、Ｃ 1 〜Ｃ 4 アルキルチオ、Ｃ 1 〜Ｃ 4 アルキルスルフィニル、Ｃ 1 〜Ｃ 4 アルキルスルホニル、カルバモイル、Ｎ−Ｃ 1 〜Ｃ 4 アルキルカルバモイル、Ｎ，Ｎ−ジ（Ｃ 1 〜Ｃ 4 アルキル）カルバモイル、アミノスルホニル、Ｎ−Ｃ 1 〜Ｃ 4 アルキルアミノスルホニル、Ｎ，Ｎ−ジ（Ｃ 1 〜Ｃ 4 アルキル）アミノスルホニル、Ｃ 1 〜Ｃ 4 アルキルスルホニルアミノ、又は基Ｒ 4 Ｘ 1 を表し、その際、Ｘ 1 は直接結合、Ｃ 2 〜Ｃ 4 アルカノイル、−ＣＯＮＲ 5 Ｒ 6 −、−ＳＯ 2 ＮＲ 7 Ｒ 8 −又は−ＳＯ 2 Ｒ 9 −を表し（その際、Ｒ 5 及びＲ 7 は相互に無関係に、水素又はＣ 1 〜Ｃ 2 アルキルを表し、Ｒ 6 、Ｒ 8 及びＲ 9 は相互に無関係に、Ｃ 1 〜Ｃ 4 アルキルを表し、その際、Ｒ 4 はＲ 6 、Ｒ 8 又はＲ 9 と結合している）及びＲ 4 は、フェニル及び５又は６員の複素環式基から選択された場合により置換された基を表し；ｎは０−４の整数を表し；Ｒ 1 は水素、Ｃ 1 〜Ｃ 4 アルキル、Ｃ 1 〜Ｃ 4 アルコキシメチル、ジ（Ｃ 1 〜Ｃ 4 アルコキシ）メチル又はＣ 1 〜Ｃ 4 アルカノイルを表し；ｍは０−４の整数を表し；及びＲ 3 はヒドロキシ、ハロゲノ、ニトロ、トリフルオロメチル、Ｃ 1 〜Ｃ 3 アルキル、シアノ、アミノ又はＲ 10 Ｘ 2 を表し（その際、Ｘ 2 は直接結合、−ＣＨ 2 −、又は−Ｓ−、−ＳＯ−及び−ＮＲ 15 −を含めた１つ又は２つのヘテロ原子結合基を表し（その際、Ｒ 15 は水素、Ｃ 1 〜Ｃ 3 アルキル又はＣ 1 〜Ｃ 3 アルコキシＣ 2 〜Ｃ 3 アルキルを表し）、及びＲ 10 は、例えばヒドロキシ、アミノ、ニトロ、アルキル、シクロアルキル、アルコキシアルキルにより場合により置換されたアルケニル又はアルキニル鎖、又はピリドン、フェニル及び複素環から選択される場合により置換された基を表し、アルキル、アルケニル又はアルキニルサハヘテロ原子結合基を有していてもよく、又はＲ 10 はピリドン、フェニル及び複素環から選択される場合により置換された基を表す］の化合物に関する。式Ｉの化合物及びその調剤学的に認容性の塩は、VEGF及びFGFの作用を阻害し、ガン及びリュウマチ性関節炎を含めた一連の疾病状態を治療することができる。
Patent JP-2001520549-A (JP)
Title: 外科用器具
IPC: A61M1/00
Filed: 1998-04-09
Abstract: (57)【要約】
患者の皮膚に開口部を形成する外科用器具は、皮膚の一側部に適用される第一の本体と、該第一の本体と協働し得るように皮膚の他の側部に適用される、切開要素を有する第二の本体という２つの本体を備えている。第一及び第二の本体を皮膚の両側部に配置し且つ切開要素を移動させることにより、簡単に且つ安全に皮膚に開口部が形成される。
Patent NZ-191589-A (NZ)
Title: 5-((r)-1-hydroxy-2-((r)-(1-methyl-3-phenylpropyl)-amino)-ethyl)-salicylamide and derivatives; intermediates; pharmaceutical compositions
Inventor: GOLD E H
IPC: A61P25/02
Filed: 1979-09-17
Abstract: The (R,R) optical isomer of labetalol, namely 5-[ (R)-1-hydroxy- 2-[(R)-1-methyl- 3-phenylpropyl)amino ]ethyl]salicylamide, and its pharmaceutically acceptable acid addition salts, in a state substantially free of the corresponding (R,S), (S,R) and (S,S) optical isomers, are novel compounds with favourable therapeutic properties in comparison with labetalol. They can be used in particular in the treatment of hypertension. The novel (R,R) optical isomer and its pharmaceutically acceptable acid addition salts can be prepared by removal of the protecting groups from an N,O-protected (R,R) optical isomer or acid addition salt thereof, wherein the basic nitrogen atom and the phenolic hydroxy group are protected, preferably by hydrogenolytic removal of hydrogenolysable groups.
Patent NZ-196768-A (NZ)
Title: Recombinant dna method for synthesising mature protein or polypeptide,without signal sequence or other chemical substituents:recombinant cloning vehicle encoding protein or polypeptide precursor
Inventor: GILBERT W
IPC: C12N1/20
Filed: 1981-04-09
Abstract: A method is provided for synthesizing within a bacterial host. and secreting through the membrane of the host, a se- locted mature protein or polypeptide. The method involves:a) cleaving a cloning vehicle to form a cleavage site after a promoter of either 1) a bactenal or phage gene within the cloning vehicle or 2) a DNA fragment of the bacterial or phage gene.b) forming a hybnd gene by mserting into the cleavage site a non-bacterul DNA fragment which codes for precursor of the selected protein or porypeptide. mcluding the signal sequence of the selected protem or potypeptrde:c) transtormung the host with the cloning vehicle; and thend) cuttunng the transformed host to secrete the selected protem or potypeptideBy this method mature proteins or polypeptides can be produced tree of sugnal sequences or other chemical substituents. such as an f-mel. on the protems or potypeptides.
Patent NZ-239331-A (NZ)
Title: Enhancing the surface area of adsorbent polymers of aromatic monomers having pendant vinyl groups by treatment with a lewis acid in a non-swelling solvent
Inventor: METEYER THOMAS EDWARD
IPC: B01J20/26
Filed: 1991-08-09
Abstract: Highly crosslinked adsorbent copolymers are treated to enhance their surface area by reacting the copolymers in the presence of non-swelling liquid and Lewis-acid catalyst.
Patent NZ-240577-A (NZ)
Title: Tissue factor-based prothrombin time reagent comprising a liposome composition
Inventor: BROWN SCOTT MARTIN
IPC: G01N33/543
Filed: 1991-11-13
Abstract: Prothrombin time reagents are provided which comprise novel liposome compositions in which tissue factor is associated with an inserted into the phospholipid bilayer of the liposomes. Methods for their preparation are also provided. The liposome compositions may be adjusted to allow maximum coagulant activity and sensitivity to extrinsic coagulation factors.
Patent NZ-244613-A (NZ)
Title: A ligand containing a hypoxia-localising moiety, preparation thereof; a kit (optionally multivial) for preparing a metal complex containing the ligand
Inventor: LINDER KAREN
IPC: C07C251/34
Filed: 1992-10-05
Abstract: A compound of the formulae <CHEM> where at least one R  is -(A)<sb>p</sb>-R2 where (A)<sb>p</sb> is a linking group and R2 is a hypoxia localizing noiety; and wherein the other R groups are the same, or different and are independently selected from hydrogen, halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, aryl, -COOR3, <CHEM> -NH2, hydroxyalkyl, alkoxyalkyl, hydroxyaryl, haloalkyl, arylalkyl, -alkyl-COOR3, -alkyl-CON(R3)2, alkyl-N(R3)2, -aryl-COOR3, -aryl-CON(R3)2, -aryl-N(R3)2, 5- or 6-membered nitrogen- or oxygen-containing heterocycle; or two R groups taken together with the one or more atoms to which they are attached form a carbocyclic or heterocyclic, saturated or unsaturated spiro or fused ring which may be substituted with R groups;     R1  is hydrogen, a thiol protecting group or -(A)<sb>p</sb>-R2;     R3 is hydrogen, alkyl or aryl;     m = 2 to 5; p = 0 to 20 A)<s
Patent NZ-247792-A (NZ)
Title: Retention device for drainage tube: toothed strap and squeeze-release latching means
Inventor: SCHNEIDER BARRY L
IPC: A61M27/00
Filed: 1993-06-04
Abstract: A retention device (10), particularly useful for drainage tubes and the like, having a pad (11) for adhesive attachment to a patient's skin at the exit/entry site for a post-surgical drainage tube. The device includes a retainer body (13) secured to the pad and provided with a strap (14) to be looped and tightened about the drainage tube for immobilizing that tube. A passage in the body receives the free end of the strap and a latching mechanism (28) prevents retraction of the strap unless a pair of side flanges (26) of the body are squeezed towards each other to alter the configuration of the body's top wall (27) and cause upward disengagement of a restraining pawl from the ratchet teeth of the strap. In one form of the invention, the strap is oriented horizontally and the passage is spaced well above the pad so that the horizontal plane of the passage substantially bisects the loop along its axis, thereby allowing portions of the loop to be located above and below the entrance to the passage. In another embodiment, the strap is oriented in a vertical plane and the pawl is cammed laterally and upwardly to disengage the strap when the side flanges are squeezed towards each other. <IMAGE>
Patent NZ-248618-A (NZ)
Title: 6-hydroxy-2-thiocarbamyl(methyl)-benzofuran derivatives and pharmaceutical compositions
Inventor: LE BAUT GUILLAUME
IPC: A61K31/44
Filed: 1993-09-08
Abstract: Compounds of formula (I): <IMAGE> in which R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description,  their optical isomers, and their addition salts with a pharmaceutically acceptable acid or base. Medicaments.
Patent NZ-255216-A (NZ)
Title: 6-halo-4-perhalomethyl(or ethyl)-2-oxo-3,1-benzoxazine derivatives and pharmaceutical compositions
Inventor: YOUNG STEVEN D
IPC: C07D453/00
Filed: 1993-08-06
Abstract: Certain benzoxazinones of the formula: <CHEM>  wherein:     X is halo,     X<1> is trihalomethy, or pentahaloethyl;     Z is O; are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Patent NZ-261815-A (NZ)
Title: Solids separated from flowing liquid by panel cleaned by liquid flow
Inventor: BLANCHE PAUL
IPC: B01D33/067
Filed: 1994-02-11
Abstract: A means separates solid matter from liquid and includes a perforated separation panel through which the liquid can pass and which prevents the passage of the solid matter of a size larger than a predetermined size. When solid matter becomes located against the panel, the flow of liquid along the face of the panel on which the solid matter is located will tend to cause the solid matter to move from the panel so that the panel is self cleaned and does not become obstructed by the solid matter.
Patent NZ-269557-A (NZ)
Title: Epoxidation catalyst; comprises silver, alkali metal, magnesium and rhenium, the catalyst being supported on an alpha alumina carrier
Inventor: EVANS WAYNE ERROL
IPC: B01J27/04
Filed: 1994-07-06
Abstract: This invention relates to an epoxidation catalyst having improved selectivity stability which catalyst comprises silver, a promoting amount of alkali metal, a promoting amount of magnesium, a promoting amount of rhenium and, optionally, a promoting amount of rhenium co-promoter selected from sulphur, molybdenum, tungsten, chromium and mixtures thereof, supported on a carrier comprising at least 85 percent by weight of alpha alumina and from 0.001 to 2 percent by weight (measured as the element) of magnesium in the form of an oxide.
Patent NZ-296925-A (NZ)
Title: Compositions comprising n-alkoxyalkylamide and imide derivatives
Inventor: MULLER GEORGE
IPC: A61K31/44
Filed: 1995-11-20
Abstract: Novel imide/amide ethers are inhibitors of tumor necrosis factor alpha  and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is 1-Phthalimido-1-(3',4'-dimethoxyphenyl)propan-1-ol.
Patent NZ-298662-A (NZ)
Title: Carbonated semi-solid or solid spoonable food, e.g. yogurt, custard, gelatin or icecream
Inventor: OGDEN LYNN V
IPC: A23L1/00
Filed: 1995-12-11
Abstract: A process to add carbon dioxide under low shear conditions to an already formed food to produce a semi-solid or solid carbonated food. The carbonated semi-solid or solid spoonable food has the following properties: (a) a viscosity of between about 2000 and 200,000 centipoise at between about 1.5 DEG  and 25 DEG  C., and (b) a carbonation level of between about 0.5 and 4.0 volumes of carbon dioxide per volume of food. The process includes contacting the formed food with carbon dioxide gas with low shear agitation.
Patent NZ-299645-A (NZ)
Title: Nicotinamide derivatives; use in treating inflammation
Inventor: CHENG JOHN B
IPC: A61P15/00
Filed: 1996-10-25
Abstract: The use of a compound of formula I for the manufacture of a medicament for the inhibition of phosphdiesterase type IV or the production of tumour necreosis.  R3 is an optionally substituted aryl, heteroaryl or alkyl group; R4 is bicyclo[2.2.1]hept-2-yl group or a phenyl group optionally substituted in the 3 and/or 4 positions with a group selected from fluoro, chloro, methoxy, trifluoromethyl, cyano, carboxy, methylcarbamoyl, dimethyl-carbamoyl or carbo(C1-C4)alkoxy
Patent NZ-332023-A (NZ)
Title: Segmented pipe coupling including a recess in at least one of the bolting pads for the head of a T-bolt
Inventor: DOLE DOUGLAS R
IPC: F16B35/06
Filed: 1998-09-22
Abstract: A segmented pipe coupling comprises a plurality of coupling segments 10, 12 having a bolting pad 22a, 24a at each end thereof.  Each pad provides a bolting face 22, 24 and at least one of the pads includes a recess 26 in the bolting face for the reception of a head 28 of a T-bolt.  The recess has two end faces.  The bolding pads have an aperture 30 for permitting the insertion of a threaded shank 29 of the T-bolt therethrough.  The head of the T-bolt defines a pivotal axis and is receivable within recess 26.  Recess 26 defines a corresponding pivotal axis.  The head 28 of the T-bolt has end faces positionable opposite the respective end faces of the recess.  A nut 32 is threaded onto shank 29 and has an operative face for operative surface engagement in a manner to interconnect the pads 22a, 24a whereby the shank can move relative to the associated pad into a position in which an operative surface portion of the head 28 and an operative surface of the nut 32 are in continuous face engagement with the respective associated adjacent operative surfaces to maintain the coupling segments in interconnected relation.  The end faces of the recess provide resistance to rotation of the end faces of the head.
Patent NZ-332598-A (NZ)
Title: Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell
Inventor: LIU YONG-JUN
IPC: A61K38/00
Filed: 1997-05-15
Abstract: An isolated or recombinant nucleic acid encoding a human BAS-1 protein, functionally equivalent fragment thereof comprising the SEQ ID NO 1 or SEQ ID NO 2, protein comprising nucleic acid, fusion protein, antibody binding fragment which binds BAS-1 proteins or fragments, vector and host cell, and use of an antagonist or a primate BAS-1 protein for modulating physiology or development of a cell. Further claimed is a use of an agonist or antagonist of a primate BAS-1 protein in combination with a mediator of a signal through the antigen receptor, the CD40:CD40 ligand pathway or the CD28/CTLA-4:B7/B70 pathway  for modulating physiology or development of a cell.
Patent NZ-332800-A (NZ)
Title: Adaptive signal quality adjustment in a cellular telecommunication system
Inventor: KARLSSON PATRIK
IPC: H04B17/00
Filed: 1997-06-06
Abstract: Signal quality in a cell or cells of a cellular telephone system is improved by first determining a filtered transmitter power level that represents transmitted power levels in the cell or cells.  The filtered transmitter power level is used to determine a new adaptive signal quality reference level.  Finally, the new adaptive signal quality reference level is used to adjust the individual transmitter units in the cell or cells so that the actual received signal quality experienced by the communication links in the cell or cells substantially equals the new adaptive signal quality reference level.
Patent NZ-333017-A (NZ)
Title: Cable for use in transformer or dynamoelectric machine, insulation layer between two semiconducting layers
Inventor: LEIJON MATS
IPC: H02K3/14
Filed: 1997-05-27
Abstract: This electromagnetic device comprises a magnetic field generating an electrical circuit including a winding (1) having at least one electrical conductor (2).  The winding comprises a solid insulation (4) surrounded by outer and inner layers (3, 5) serving for equalization of potential and having semiconducting properties.  The at least one electrical conductor (2) is arranged interiorly of the inner semiconducting layer (3).  The application also relates to methods for electric field control and production of a magnetic circuit as well as use of a cable for obtaining a winding.
Patent NZ-333904-A (NZ)
Title: VLA-4 and IIb/IIIa cell adhesion inhibitors
Inventor: ZHENG ZHONGLI
IPC: C07D401/04
Filed: 1997-07-24
Abstract: The VLA-4 (Very Late Antigen of activation-4, also known as alpha-4-beta-1 integrin) inhibitor has the basic formula A-B, wherein A comprises a VLA-4 specificity determinant, and B comprises an integrin scaffold derived from a compound having IIb/IIIa activity. Examples of groups from which A is selected include; alkyl, aliphatic acyl optionally substituted with N-alkyl or N-arylamido, aroyl, heterocycloyl, alkylaminocarbonyl, alkyl- and arylsulfonyl, aralkylcarbonyl optionally substituted with aryl, heterocycloalkylcarbonyl or other group. Formulae IIa, IIb and IIc represent examples of compounds from which B is selected. A1 is NR1, O, S, (CR1R2)r or N[(CR1R2)m(C=Y)A2R1]; A3 is O, NR2, S or (CR1R2)r; X is H2, O or S; m is 1-4; n is 0-5; W is CO2H, SO3H, PO4H2, tetrazole or H; U is COR12, (CR1R2)n R12 or SO2R11; R1 and R2 are independently H, optionally substituted alkyl, alkenyl, cycloalkenyl, heterocycle or other group; R3 is R1 or amino acid side chain; R5 and R6 are independently H, OR1, halogen, alkyl, SR1, NZR12 or NR1R2; r is 0 or 1; A2 is O, NR2, S or (CR1R2)r; Y is H2 or O; Z is CO or CR1R2)n; R11 is optionally substituted alkyl, cycloalkyl, alkenyl, aryl, heterocycle or other group; R12 is H, optionally substituted alkyl, cycloalkyl, aryl, heterocycle or other group. The inhibitor has an IC50 of 1pM to 10uM as measured by a VLA-4 direct binding assay. A medicament comprising the compounds of formulae A-B can be used as therapeutic or prophylactic agents for the treatment of inflammatory and autoimmune diseases, asthma, adult respiratory distress syndrome, multiple sclerosis and diabetes. The IIb/IIIa inhibitor has the basic formula X-Y, wherein X comprises a IIb/IIIa specificity determinant and Y comprises an integrin scaffold derived from a VLA-4 inhibitor.
Patent NZ-336540-A (NZ)
Title: Container having two or more compartments having a displaceable member which is fitted into and engaged at bottom end of the container
Inventor: INBAR MICHAEL
IPC: A61J9/00
Filed: 1997-12-25
Abstract: Described is a container (10) for storing two components separately and then mixing them prior to use.  The container includes a housing (12) with an opening (14) and a neck portion (16), a displaceable member (20), and a closure member (48). The housing (12) is formed with a first compartment (12) and a second compartment (38) intercommunicating at the neck portion. The displaceable member (20) has a partition wall (22) for sealing the neck portion. The displaceable member is formed such that the partition wall (22) moves from a non-sealing position in which the first (18) and second (38) compartments intercommunicate to a sealing position in which the neck portion (16) is sealed. The displaceable member (20) also may feature at least one conduit for allowing introduction of a component through the opening into the housing. The closure member seals the at least one conduit of the displaceable member and/or the opening of the housing (12). The displaceable member (20) may be moved by rotating, pushing or pulling and may be moveable by a portion exterior to the housing (12). The seal formed by the partition wall (22) of the displaceable member may be reformable, that is, capable of being resealed. The two-compartment container may also include a dosing assembly for dispensing a predetermined quantity of mixed formulation.
Patent NZ-500565-A (NZ)
Title: Process for the removal of heavy metals from organic material where the organic compound in a solvent is treated with a cysteine derivative
Inventor: VILLA MARCO
IPC: C07B63/02
Filed: 1998-05-04
Abstract: A method for the removal of heavy metals from solutions of organic compounds by treatment with cysteine or with an N-acylcysteine is described. Organic compounds with a content of heavy metal, for example palladium, particularly low and suitable for the preparation of compounds with pharmacologic activity can be isolated from the resultant solutions. Wherein; R is a hydrogen atom, a linear or branched C1-6acyl group or benzoyl group.
Patent NZ-501929-A (NZ)
Title: Omeprazole sodium salt
Inventor: GUSTAVSSON ANDERS
IPC: A61K31/00
Filed: 1998-06-11
Abstract: This form of the sodium salt of 5-methoxy-2-[ [(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]sulfinyl]-1H-benzimidazole (omeprazole sodium form B) is characterized by the X-ray diffraction pattern in the table above. The salt may be prepared by adding an aqueous Na+B- base to omeprazole in a solvent mixture comprising an alcohol and water, allowing the solution to crystallize, optionally using omeprazole sodium form B to induce crystallization, and isolating the omeprazole sodium form B thus obtained. The salt may be used in medicaments for intravenous administration in the treatment of gastrointestinal disorders.